Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
US Army
Cipla
Farmers Insurance
US Department of Justice
Daiichi Sankyo
Dow
McKesson
Fuji

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,960,370

« Back to Dashboard

Which drugs does patent 7,960,370 protect, and when does it expire?

Patent 7,960,370 protects EPANOVA and is included in one NDA.

This patent has twenty-three patent family members in twenty-one countries.
Summary for Patent: 7,960,370
Title:Type A gelatin capsule containing PUFA in free acid form
Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
Inventor(s): Sachetto; Jean-Pierre (Arlesheim, CH), Bufton; Roly (Bubendorf, CH), Buser; Thomas (Nuglar, CH)
Assignee:
Application Number:10/587,201
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Drugs Protected by US Patent 7,960,370

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,960,370

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0403247.0Feb 13, 2004
PCT Information
PCT FiledFebruary 07, 2005PCT Application Number:PCT/GB2005/000415
PCT Publication Date:September 01, 2005PCT Publication Number: WO2005/079853

Non-Orange Book US Patents Family Members for Patent 7,960,370

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,132,112 Type A gelatin capsule containing PUFA in free acid form ➤ Try a Free Trial
9,729,321 Autonomous private key recovery ➤ Try a Free Trial
8,383,678 Type a gelatin capsule containing PUFA in free acid form ➤ Try a Free Trial
9,012,501 Type A gelatin capsule containing PUFA in free acid form ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,960,370

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus 1110030 ➤ Try a Free Trial
Canada 2555064 ➤ Try a Free Trial
Germany 602005019402 ➤ Try a Free Trial
China 1929824 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Deloitte
Chubb
Cipla
Johnson and Johnson
Fuji
AstraZeneca
Covington
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.